Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.49 |
| ▸ | FEN1 | P39748 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31056701 | 0.83 | TDP1 (0.50) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL29324954 | 0.83 | TDP1 (0.50) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL31056870 | 0.81 | ALDH1A1 (0.48) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL30436770 | 0.81 | MAPT (0.51) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL595530 | 0.81 | MAPT (0.51) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL29324953 | 0.81 | ALDH1A1 (0.48) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL5543060 | 0.81 | MKNK1 (0.65) | ALOX5APFEN1KDM4EALDH1A1CA1 | |
| SCHEMBL29598250 | 0.80 | MAPK1 (0.61) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL15203084 | 0.80 | MKNK1 (0.64) | ALOX5APFEN1MAPK1SMN1; SMN2 | |
| SCHEMBL15203108 | 0.80 | CSNK2A1 (0.58) | ALOX5APFEN1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194741-A1 | NEW ANTI-MALARIAL AGENTS | UNIVERSITY OF CAPE TOWN (ZA) | 2018-07-12 | — | — | US | disclosed |
| US-20180194741-A1 | NEW ANTI-MALARIAL AGENTS | UNIVERSITY OF CAPE TOWN (ZA) | 2018-07-12 | — | — | US | disclosed |
| EP-2457913-B1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARM LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2090577-B1 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3118198-A1 | ANTI-MALARIAL AGENTS | MMV Medicines for Malaria Venture (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-9266842-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-02-23 | — | — | US | disclosed |
| US-9266842-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-02-23 | — | — | US | disclosed |
| US-20150031682-A1 | ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-01-29 | — | — | US | disclosed |
| US-8372976-B2 | Methods of treatment comprising the administration of heteroaryl compounds | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2457913-A2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2078016-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-06 | — | — | US | disclosed |
| US-7981893-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-07-19 | — | — | US | disclosed |
| CN-101573360-A | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC (US) | 2009-11-04 | — | — | CN | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031682-A1 | ANTI-MALARIAL AGENTS | QDPR, DHFR, IL5 | ALOX5AP 131/4885FEN1 4372/4885KDM4E 578/4885 |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | JAK2, GLS2, NFKBIA | ALOX5AP 1945/4885FEN1 2515/4885KDM4E 2244/4885 |
| US-20180194741-A1 | NEW ANTI-MALARIAL AGENTS | QDPR, API5, DHFR | ALOX5AP 176/4885FEN1 4608/4885KDM4E 561/4885 |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | ALOX5AP 1433/4885FEN1 2236/4885KDM4E 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.